Veracyte Signs a Multi-Year Agreement with Illumina to Enhance its IVD Test for the Patients Globally
Shots:
- The partnership will develop high-performing molecular tests for Illumina's NextSeq 550Dx NGS instrument as part of a broader IVD approach which also incl. qPCR. This aims to expand global patient access to Veracyte's tests
- Veracyte will develop Prosigna Breast Cancer Assay and Percepta Nasal Swab test for Illumina's NextSeq 550Dx instrument. Prosigna aids in breast cancer treatment decisions, and Percepta assists in diagnosing and treating lung nodules in current and former smokers
- Illumina's NextSeq 550Dx is a trusted platform in 60+ countries for clinical applications in oncology, reproductive health, and genetic disease testing, offering a validated mid-throughput solution
Ref: Businesswire | Image: Veracyte
Related News:- Veracyte Signs a Multi-Year Agreement with AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
